Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

BioNewsCast Press Release Distribution Service

Statins: The World Market, 2009-2024

Liver Cancer Drug Pipeline Update 2008

Bioinformatics Markets

New Products

Live Cell & Kinetic HCS Imaging Trends 2008

2008 Trends to Watch: Healthcare Technology

2009 Trends to Watch: Healthcare Technology

Biosimilars Series: Stakeholder Analysis

Biotech M&A Strategies: Deal assessments, trends and future prospects

Building a Network of Networks to Achieve Interoperability in Healthcare (Strategic Focus)

Business Trends - Healthcare Technology (Customer Focus)

Claims Processing for Healthcare Payers (Market Model)

Clinical Decision Support in Healthcare - One step closer to the Omniscient Clinician (Strategic Focus)

Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential

BioPortfolio | Life Science Analytics | Genetic Diseases and Dysmorphic Syndromes Gaucher's Disease Drug Pipeline Report

Genetic Diseases and Dysmorphic Syndromes Gaucher's Disease Drug Pipeline Report

Life Science Analytics', "Genetic Diseases and Dysmorphic Syndromes - Gaucher's Disease Drug Pipeline Report" contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of gaucher's disease drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Life Science Analytics’ Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company’s full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development. Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

* Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

* Keep track of your competitors and partners by better understanding their product pipeline.

* Monitor a company’s research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

* Maintain a critical competitive advantage.

Updated Monthly

Pages: 10

PDF Format
Table of Contents
Price: $995.00 / €714.01

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions